Peripheral interventions

Phoenix atherectomy for patients with peripheral artery disease

EuroIntervention 2022;18:e432-e442. DOI: 10.4244/EIJ-D-21-01070

Sorin Giusca
Sorin Giusca1, MD; Saskia Hagstotz1, MS; Michael Lichtenberg2, MD; Ulrike Heinrich3, MD; Christoph Eisenbach4, MD; Martin Andrassy5, MD; Grigorios Korosoglou1, MD
1. GRN Hospital Weinheim, Cardiology and Vascular Medicine, Weinheim, Germany; 2. Vascular Center Klinikum Arnsberg, Arnsberg, Germany; 3. Practice for Vascular Medicine and Gastroenterology, Weinheim, Germany; 4. GRN Hospital Weinheim, Diabetology and Gastroenterology, Weinheim, Germany; 5. Fuerst-Stirum Hospital, Cardiology and Vascular Medicine, Bruchsal, Germany

Background: Endovascular atherectomy enables minimally invasive plaque removal in peripheral artery disease (PAD).

Aims: We aimed to evaluate the safety and the long-term effectiveness of the Phoenix atherectomy for the treatment of complex and calcified lesions in PAD patients.

Methods: Consecutive all-comer patients with PAD underwent the Phoenix atherectomy. Device safety in terms of perforation and distal embolisation were evaluated. Lesion calcifications were categorised by the Peripheral Arterial Calcium Scoring System (PACSS) and lesion complexity was assessed by the Transatlantic Inter-Society Consensus (TASC). Clinically driven target lesion revascularisation (TLR) was assessed.

Results: A total of 558 lesions were treated in 402 consecutive patients. Clinical follow-up was available at 15.7±10.2 months for 365 (91%) patients. Of 402 patients, 135 (33.6%) had claudication, 37 (9.2%) had ischaemic rest pain and 230 (57%) exhibited ischaemic ulcerations. Lesions were mostly identified in the femoropopliteal segments (55%), followed by below-the-knee (BTK) segments (32%). Complex TASC C/D lesions and moderate to severe calcifications (PACSS score ≥2) were present in 331 (82%) and 323 (80%) patients, respectively. The mean lesion length was 20.6±14.3 cm. Five (1%) perforations and 10 (2%) asymptomatic embolisations occurred. Bail-out stenting was performed in 4%, 16% and 3% of patients with common femoral artery, femoropopliteal and BTK lesions, respectively. During follow-up, 5 (3.9%) patients with claudication and 52 (21.9%) patients with critical limb-threatening ischaemia (CLTI) died (hazard ratio [HR] 3.7; p<0.001). Freedom from TLR was 87.5% (112 of 128) in patients with claudication and 82.3% (195 of 237) in patients with CLTI, respectively (HR 1.8; p=0.03).

Conclusions: The Phoenix atherectomy can be safely performed in patients with complex lesions with a relatively low rate of bail-out stenting and clinically acceptable TLR rates. German Clinical Trials Register: DRKS00016708

Sign in to read and download the full article

Forgot your password?

No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

atherectomybelow the knee diseaseclaudicationcritical limb ischaemiadrug-eluting balloonfemoropopliteal disease
Read next article
Percutaneous left atrial appendage closure with superior vascular access

Latest news